Literature DB >> 12122539

Successful treatment of a complicated case of neuroleptic malignant syndrome.

A Lappa1, M Podestà, O Capelli, A Castagna, G Di Placido, D Alampi, F Semeraro.   

Abstract

Neuroleptic malignant syndrome (NMS) is a life-threatening reaction often related to neuroleptic drugs, characterized by rigidity, hyperthermia, altered consciousness, and fluctuating blood pressure. We present a case of NMS that followed a doubled oral dose of a drug compound: tranylcypromine sulfate, a monoamine oxidase inhibitor, and trifluoperazine (neuroleptic). The case was complicated by rhabdomyolisis and disseminated intravascular coagulation. It was treated successfully with dantrolene sodium and generous fluid therapy without using neuromuscular blocking agents or dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122539     DOI: 10.1007/s00134-002-1241-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  4 in total

1.  Neuroleptic malignant syndrome masked by cerebral malaria.

Authors:  Kumar Muniandy Rajesh; Vellan Sinnathamby; Arul N Sakthi
Journal:  BMJ Case Rep       Date:  2013-05-22

2.  Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.

Authors:  Gennady Cherednichenko; Chris W Ward; Wei Feng; Elaine Cabrales; Luke Michaelson; Montserrat Samso; José R López; Paul D Allen; Isaac N Pessah
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

3.  Neuroleptic malignant syndrome and closed head injury: A case report and review.

Authors:  Nissar Shaikh; Ghanem Al-Sulaiti; Abdel Nasser; Muhammad Ataur Rahman
Journal:  Asian J Neurosurg       Date:  2011-07

4.  Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report.

Authors:  Francesco Piacenza; Suet Kee Ong; Patrick O'Brien; Maurice Clancy
Journal:  Clin Case Rep       Date:  2021-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.